

Zydus receives final approval from the USFDA for Valacyclovir Tablets USP

Ahmedabad, December 30, 2017

Zydus Pharmaceuticals (USA) Inc., a wholly owned subsidiary of Cadila Healthcare Limited, has received the final approval from the USFDA to market Valacyclovir Tablets USP in strengths of 500 mg and 1 gm. The drug is indicated for the treatment of cold sores (herpes labialis), genital herpes, chickenpox and herpes zoster (shingles). It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

The group now has more than 180 approvals and has so far filed over 310 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
